Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  IntegraGen    ALINT   FR0010908723


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

IntegraGen : Announces Publication of Data Which Demonstrates the Ability of miR-31-3p to Predict Response to Therapy for Patients with Metastatic Colorectal Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
09/04/2018 | 02:01am EST

Data published in Clinical Cancer Research reports that low miR-31-3p expression predicts improved survival and a better response to anti-EGFR therapy compared to anti-VEGF therapy in patients with metastatic colorectal cancer enrolled in the FIRE-3 clinical trial

Regulatory News:

IntegraGen (FR0010908723: ALINT - PEA-SME Eligible), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announced the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer” was published online in Clinical Cancer Research, a leading oncology journal which focuses on innovative clinical and translational cancer research studies that bridge the laboratory and the clinic.

The study found that a low expression of the miR-31-3p biomarker predicts both improved survival and treatment response in patients receiving anti-EGFR therapy. In addition to confirming miR-31-3p is predictive of outcomes for RAS WT mCRC patients treated with anti-EGFR therapy, the study also found that patients with a miR-31-3p expression below a pre-defined threshold have a one year longer median overall survival, a 40% reduction in mortality risk, and a better treatment response when they are treated with FOLFIRI plus cetuximab compared to FOLFIRI plus bevacizumab. Conversely, no difference in outcomes was seen between the two treatment groups in patients with miR-31-3p expression above the pre-defined threshold. These results support the use of miR-31-3p expression testing in primary tumors from RAS WT mCRC patients to assist clinicians to identify the most appropriate first line biologic therapy may be most beneficial.

“The results of our study demonstrate the ability for miR-31-3p to predict which patients with RAS wild-type metastatic colorectal cancer will have improved outcomes when treated in first line with cetuximab compared to bevacizumab when combined with FOLFIRI therapy,” explained Prof. Dr. Sebastian Stintzing, an oncologist from University Hospital, LMU Munich in Munich, Germany and lead author on the paper. “These findings are particularly significant since nearly two-thirds of the patients with RAS wild-type tumors in our study had low miR-31-3p expression levels and would therefore benefit from being treated with cetuximab versus bevacizumab as first line therapy for mCRC.”

“The results from this study confirm the ability of the miR-31-3p biomarker to predict anti-EGFR therapy response, and in turn, demonstrates the clinical utility of this biomarker for patients with metastatic colorectal cancer,” stated Dr. Bernard Courtieu, IntegraGen’s CEO. “This data demonstrates that the use of miR-31-3p expression testing can guide the choice of first line biologic therapy in RAS wild-type patients and enable oncologists to better select a personalized therapeutic approach, resulting in an improved opportunity for positive patient outcomes and decreased cost of care.”

IntegraGen will presenting new data reporting positive results from an analysis of miR-31-3p expression in over 1,400 resected stage III colon cancer patients enrolled in the PETACC-8 trial during the upcoming 2018 Annual Meeting of the European Society for Medical Oncology October 19-23 in Munich, Germany.

IntegraGen has commercialized the miRpredX 31-3p kit, a proprietary IVD CE Marked kit and has also licensed its intellectual property associated with miR-31-3p to GoPath Laboratories for the North American market. GoPath Labs recently announced the commercial launch of miR-31now, a laboratory developed test which measures miR-31-3p expression in FFPE specimens.


The FIRE-3 (AIO KRK-0306) clinical trial is an independent, randomized, controlled Phase III trial conducted in Europe and led by University Hospital, LMU Munich, Germany. The study compares outcomes of KRAS Exon 2 wild-type (WT) stage IV colorectal cancer patients randomized to receive FOLFIRI therapy (5-FU, folinic acid and irinotecan) in combination with either cetuximab or bevacizumab.


IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2017, IntegraGen had 40 employees and had generated revenue of €6.1 million in 2017. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com

© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on INTEGRAGEN
09/23INTEGRAGEN : Half-year results
06/30INTEGRAGEN : Press release on General Assembly voting results
03/05INTEGRAGEN : and Advanced Biological Laboratories Sign Global Licensing Agreemen..
2018INTEGRAGEN : Half-year results
2018INTEGRAGEN : Announces Publication of of miR-31-3p Data in Clinical Cancer Resea..
2018INTEGRAGEN : Announces Publication of Data Which Demonstrates the Ability of miR..
2018INTEGRAGEN : Monthly statement on outstanding equity shares and voting rights
2018INTEGRAGEN : The SeqOIA Cooperative Health Group Selects IntegraGen As the Opera..
2018INTEGRAGEN ACHIEVES ISO 13485 : 2016 Certification for the Design, Manufacturing..
2018INTEGRAGEN : Presents Data from Liquid Biopsy Studies of Proprietary miRNAs duri..
More news
Financials (EUR)
Sales 2019 9,80 M
EBIT 2019 -0,20 M
Net income 2019 -0,20 M
Finance 2019 2,20 M
Yield 2019 -
P/E ratio 2019 -32,7x
P/E ratio 2020 -
EV / Sales2019 0,42x
EV / Sales2020 0,43x
Capitalization 6,34 M
Duration : Period :
IntegraGen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTEGRAGEN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 1
Average target price 4,15  €
Last Close Price 0,98  €
Spread / Highest target 323%
Spread / Average Target 323%
Spread / Lowest Target 323%
EPS Revisions
Bernard Courtieu Chairman & Chief Executive Officer
Laurence Riot Lamotte Chief Financial Officer
Gerald D. Wagner Director
Peter Behner Director
Yannick Sabatin Director
Sector and Competitors
1st jan.Capitalization (M$)
VERACYTE, INC.126.63%1 392